President Donald Trump signed $1.4 trillion in spending bills Dec. 20 that includes a $212.5 million increase for NCI to cope with an avalanche of grant applications and improve the institute’s declining success rates.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
